Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TNG.PA doses first patient in phase-1/2 trial TG6002:
https://finance.yahoo.com/news/first-patient-dosed-phase-1-160000972.html
TNG.PA’s HBV presentation at AASLD:
https://www.businesswire.com/news/home/20181010005608/en
TNG.PA climbs on the neoantigen bandwagon:
https://finance.yahoo.com/news/transgene-unveils-myvactm-individualized-immunotherapy-154500957.html
TNG.PA 2Q18 results:
https://finance.yahoo.com/news/transgene-presents-2018-half-results-154500903.html
6/30/18 cash was $38.6M (€33.1M) after burning $3.0M (€2.6M) during 2Q18. Guidance for 2H18 cash burn is $19.4M (€16.6M), implying projected a cash balance at 12/31/18 of $19.2M.
New corporate slide set:
https://www.transgene.fr/wp-content/uploads/2018/09/Transgene-corporate-presentation-H1-results-19-sept.pdf
TNG.PA completes out-license of China rights to two programs for $48M in Tasly Biopharmaceuticals stock:
https://www.businesswire.com/news/home/20180820005359/en
2Q18 results are due on 9/19/18, according to TNG.PA website:
https://www.transgene.fr/?page_id=10775#investorevents
TNG.PA’s Pexa-Vec PR from ASCO:
https://finance.yahoo.com/news/transgene-lead-oncolytic-virus-pexa-154500978.html
TNG.PA reports 1Q18 results: #msg-140343950.
TNG.PA AACR presentation:
https://www.businesswire.com/news/home/20180417006240/en
TNG.PA latest slide set (Jan 2018):
https://www.transgene.fr/wp-content/uploads/2018/01/Transgene_corporate_presentation_January2018.pdf
TNG.PA slide set from Jun2017 R&D Day:
https://www.transgene.fr/wp-content/uploads/2017/06/presentation_R_D_day.pdf
TNG.PA’s China JV doses first HBV patient in phase-1 trial of T101:
https://finance.yahoo.com/news/first-chronic-hepatitis-b-patient-164500912.html
TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression:
https://finance.yahoo.com/news/first-patient-dosed-phase-2-164500269.html
BMY is a co-sponsor of this single-arm trial, furnishing the Opdivo. The ct.g listing is at: https://clinicaltrials.gov/ct2/show/NCT03353675 .
*Since this trial was announced in Apr 2017, Transgene changed its ticker symbol from TRNG.PA to TNG.PA.
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
15
|
Created
|
12/29/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |